Comparison of body habitus in patients with pulmonary arterial hypertension enrolled in the registry to evaluate early and long-term PAH disease management with normative values from the national health and nutrition examination survey

Charles D. Burger; Aimee J. Foreman; Dave P. Miller; Robert E. Safford; Michael D. McGoon; David B. Badesch

doi:10.4065/mcp.2010.0394

Comparison of body habitus in patients with pulmonary arterial hypertension enrolled in the registry to evaluate early and long-term PAH disease management with normative values from the national health and nutrition examination survey

Charles D. Burger, Aimee J. Foreman, Dave P. Miller, Robert E. Safford, Michael D. McGoon, David B. Badesch

Pulmonary and Allergy Medicine

Research output: Contribution to journal › Article › peer-review

42 Scopus citations

Abstract

Objective: To investigate the correlation between body mass index (BMI) and pulmonary artery systolic pressure in a large population of patients with pulmonary arterial hypertension (PAH). Patients and Methods: The BMI of patients with group 1 PAH enrolled in the Registry to Evaluate Early and Long-term PAH Disease Management (REVEAL) was compared with that of age- and sex-matched controls in the National Health and Nutrition Examination Survey (NHANES) to clarify whether obesity is linked with PAH. The diagnosis of PAH was defined in REVEAL by right-sided heart catheterization. Differences in BMI and the percentage of patients considered obese (BMI ≥30) and underweight (BMI <18.5) in various subgroups of patients enrolled in REVEAL from March 30, 2006, through September 11, 2007, were determined. Results: Mean BMI was no different for patients with PAH (n=2141) than for the NHANES normal comparison group; however, the proportion of obese and underweight patients was increased in patients with PAH. Subgroup analysis demonstrated that subgroups with idiopathic PAH and those with PAH associated with drugs and toxins had both higher BMI and percentage of obese patients, whereas 3 other subgroups (those with PAH associated with congenital heart disease, connective tissue disease, and human immunodeficiency virus) had lower mean BMI. Conclusion: Mean BMI of the REVEAL patients was the same as that of the NHANES normal comparison group; however, there were higher percentages of obese and underweight patients in REVEAL. This discrepancy can be explained by the balancing effect of more overweight and underweight patients in different PAH subgroups. The reason for the increased frequency of obesity in idiopathic PAH is unknown, and additional study is needed. Trial Registration: clinicaltrials.gov Identifier: NCT00370214

Original language	English (US)
Pages (from-to)	105-112
Number of pages	8
Journal	Mayo Clinic proceedings
Volume	86
Issue number	2
DOIs	https://doi.org/10.4065/mcp.2010.0394
State	Published - Feb 2011

ASJC Scopus subject areas

Medicine(all)

Access to Document

10.4065/mcp.2010.0394

Fingerprint Dive into the research topics of 'Comparison of body habitus in patients with pulmonary arterial hypertension enrolled in the registry to evaluate early and long-term PAH disease management with normative values from the national health and nutrition examination survey'. Together they form a unique fingerprint.

Cite this

Burger, C. D., Foreman, A. J., Miller, D. P., Safford, R. E., McGoon, M. D., & Badesch, D. B. (2011). Comparison of body habitus in patients with pulmonary arterial hypertension enrolled in the registry to evaluate early and long-term PAH disease management with normative values from the national health and nutrition examination survey. Mayo Clinic proceedings, 86(2), 105-112. https://doi.org/10.4065/mcp.2010.0394

Comparison of body habitus in patients with pulmonary arterial hypertension enrolled in the registry to evaluate early and long-term PAH disease management with normative values from the national health and nutrition examination survey. / Burger, Charles D.; Foreman, Aimee J.; Miller, Dave P.; Safford, Robert E.; McGoon, Michael D.; Badesch, David B.

In: Mayo Clinic proceedings, Vol. 86, No. 2, 02.2011, p. 105-112.

Research output: Contribution to journal › Article › peer-review

Burger, CD, Foreman, AJ, Miller, DP, Safford, RE, McGoon, MD & Badesch, DB 2011, 'Comparison of body habitus in patients with pulmonary arterial hypertension enrolled in the registry to evaluate early and long-term PAH disease management with normative values from the national health and nutrition examination survey', Mayo Clinic proceedings, vol. 86, no. 2, pp. 105-112. https://doi.org/10.4065/mcp.2010.0394

Burger CD, Foreman AJ, Miller DP, Safford RE, McGoon MD, Badesch DB. Comparison of body habitus in patients with pulmonary arterial hypertension enrolled in the registry to evaluate early and long-term PAH disease management with normative values from the national health and nutrition examination survey. Mayo Clinic proceedings. 2011 Feb;86(2):105-112. https://doi.org/10.4065/mcp.2010.0394

Burger, Charles D. ; Foreman, Aimee J. ; Miller, Dave P. ; Safford, Robert E. ; McGoon, Michael D. ; Badesch, David B. / Comparison of body habitus in patients with pulmonary arterial hypertension enrolled in the registry to evaluate early and long-term PAH disease management with normative values from the national health and nutrition examination survey. In: Mayo Clinic proceedings. 2011 ; Vol. 86, No. 2. pp. 105-112.

@article{231328f4158b427a9dbcdaa95d4c5fd2,

title = "Comparison of body habitus in patients with pulmonary arterial hypertension enrolled in the registry to evaluate early and long-term PAH disease management with normative values from the national health and nutrition examination survey",

abstract = "Objective: To investigate the correlation between body mass index (BMI) and pulmonary artery systolic pressure in a large population of patients with pulmonary arterial hypertension (PAH). Patients and Methods: The BMI of patients with group 1 PAH enrolled in the Registry to Evaluate Early and Long-term PAH Disease Management (REVEAL) was compared with that of age- and sex-matched controls in the National Health and Nutrition Examination Survey (NHANES) to clarify whether obesity is linked with PAH. The diagnosis of PAH was defined in REVEAL by right-sided heart catheterization. Differences in BMI and the percentage of patients considered obese (BMI ≥30) and underweight (BMI <18.5) in various subgroups of patients enrolled in REVEAL from March 30, 2006, through September 11, 2007, were determined. Results: Mean BMI was no different for patients with PAH (n=2141) than for the NHANES normal comparison group; however, the proportion of obese and underweight patients was increased in patients with PAH. Subgroup analysis demonstrated that subgroups with idiopathic PAH and those with PAH associated with drugs and toxins had both higher BMI and percentage of obese patients, whereas 3 other subgroups (those with PAH associated with congenital heart disease, connective tissue disease, and human immunodeficiency virus) had lower mean BMI. Conclusion: Mean BMI of the REVEAL patients was the same as that of the NHANES normal comparison group; however, there were higher percentages of obese and underweight patients in REVEAL. This discrepancy can be explained by the balancing effect of more overweight and underweight patients in different PAH subgroups. The reason for the increased frequency of obesity in idiopathic PAH is unknown, and additional study is needed. Trial Registration: clinicaltrials.gov Identifier: NCT00370214",

author = "Burger, {Charles D.} and Foreman, {Aimee J.} and Miller, {Dave P.} and Safford, {Robert E.} and McGoon, {Michael D.} and Badesch, {David B.}",

note = "Funding Information: Ms Foreman and Mr Miller are employed by ICON Clinical Research, a company that receives research support from Actelion and other pharmaceutical companies. Dr McGoon serves as a consultant with Actelion, Gilead, Lung Rx, and Medtronic; has received grants from Gilead and Medtronic; and has received honoraria for his service on the REVEAL Steering Committee, which is supported by Actelion. Dr Badesch has received honoraria for service on steering committees and/or advisory boards for Actelion, Arena, Bayer, Ikaria, Gilead, Encysive Pharmaceuticals, Pfizer, GlaxoSmithKline, Lung Rx, United Therapeutics, Eli Lilly and Company, Biogen Idec, and mondoBIOTECH; has received grants from Actelion, Gilead, Encysive Pharmaceuticals, Pfizer, United Therapeutics, Lung Rx, Eli Lilly and Company, and the National Institutes of Health, National Heart, Lung, and Blood Institute; has previously been deposed in appetite suppressant litigation, serving as both a treating physician and an expert witness; and has received honoraria for his service on the REVEAL Steering Committee, which is supported by Actelion. Funding Information: We thank all patients, principal investigators, and study coordinators for their participation in REVEAL. Also, we thank Jennifer M. Kulak, PhD, of inScience Communications, a Wolters Kluwer business, for providing medical writing assistance, which was supported by Actelion Pharmaceuticals US, Inc. Copyright: Copyright 2017 Elsevier B.V., All rights reserved.",

year = "2011",

month = feb,

doi = "10.4065/mcp.2010.0394",

language = "English (US)",

volume = "86",

pages = "105--112",

journal = "Mayo Clinic Proceedings",

issn = "0025-6196",

publisher = "Elsevier Science",

number = "2",

}

TY - JOUR

T1 - Comparison of body habitus in patients with pulmonary arterial hypertension enrolled in the registry to evaluate early and long-term PAH disease management with normative values from the national health and nutrition examination survey

AU - Burger, Charles D.

AU - Foreman, Aimee J.

AU - Miller, Dave P.

AU - Safford, Robert E.

AU - McGoon, Michael D.

AU - Badesch, David B.

N1 - Funding Information: Ms Foreman and Mr Miller are employed by ICON Clinical Research, a company that receives research support from Actelion and other pharmaceutical companies. Dr McGoon serves as a consultant with Actelion, Gilead, Lung Rx, and Medtronic; has received grants from Gilead and Medtronic; and has received honoraria for his service on the REVEAL Steering Committee, which is supported by Actelion. Dr Badesch has received honoraria for service on steering committees and/or advisory boards for Actelion, Arena, Bayer, Ikaria, Gilead, Encysive Pharmaceuticals, Pfizer, GlaxoSmithKline, Lung Rx, United Therapeutics, Eli Lilly and Company, Biogen Idec, and mondoBIOTECH; has received grants from Actelion, Gilead, Encysive Pharmaceuticals, Pfizer, United Therapeutics, Lung Rx, Eli Lilly and Company, and the National Institutes of Health, National Heart, Lung, and Blood Institute; has previously been deposed in appetite suppressant litigation, serving as both a treating physician and an expert witness; and has received honoraria for his service on the REVEAL Steering Committee, which is supported by Actelion. Funding Information: We thank all patients, principal investigators, and study coordinators for their participation in REVEAL. Also, we thank Jennifer M. Kulak, PhD, of inScience Communications, a Wolters Kluwer business, for providing medical writing assistance, which was supported by Actelion Pharmaceuticals US, Inc. Copyright: Copyright 2017 Elsevier B.V., All rights reserved.

PY - 2011/2

Y1 - 2011/2

N2 - Objective: To investigate the correlation between body mass index (BMI) and pulmonary artery systolic pressure in a large population of patients with pulmonary arterial hypertension (PAH). Patients and Methods: The BMI of patients with group 1 PAH enrolled in the Registry to Evaluate Early and Long-term PAH Disease Management (REVEAL) was compared with that of age- and sex-matched controls in the National Health and Nutrition Examination Survey (NHANES) to clarify whether obesity is linked with PAH. The diagnosis of PAH was defined in REVEAL by right-sided heart catheterization. Differences in BMI and the percentage of patients considered obese (BMI ≥30) and underweight (BMI <18.5) in various subgroups of patients enrolled in REVEAL from March 30, 2006, through September 11, 2007, were determined. Results: Mean BMI was no different for patients with PAH (n=2141) than for the NHANES normal comparison group; however, the proportion of obese and underweight patients was increased in patients with PAH. Subgroup analysis demonstrated that subgroups with idiopathic PAH and those with PAH associated with drugs and toxins had both higher BMI and percentage of obese patients, whereas 3 other subgroups (those with PAH associated with congenital heart disease, connective tissue disease, and human immunodeficiency virus) had lower mean BMI. Conclusion: Mean BMI of the REVEAL patients was the same as that of the NHANES normal comparison group; however, there were higher percentages of obese and underweight patients in REVEAL. This discrepancy can be explained by the balancing effect of more overweight and underweight patients in different PAH subgroups. The reason for the increased frequency of obesity in idiopathic PAH is unknown, and additional study is needed. Trial Registration: clinicaltrials.gov Identifier: NCT00370214

AB - Objective: To investigate the correlation between body mass index (BMI) and pulmonary artery systolic pressure in a large population of patients with pulmonary arterial hypertension (PAH). Patients and Methods: The BMI of patients with group 1 PAH enrolled in the Registry to Evaluate Early and Long-term PAH Disease Management (REVEAL) was compared with that of age- and sex-matched controls in the National Health and Nutrition Examination Survey (NHANES) to clarify whether obesity is linked with PAH. The diagnosis of PAH was defined in REVEAL by right-sided heart catheterization. Differences in BMI and the percentage of patients considered obese (BMI ≥30) and underweight (BMI <18.5) in various subgroups of patients enrolled in REVEAL from March 30, 2006, through September 11, 2007, were determined. Results: Mean BMI was no different for patients with PAH (n=2141) than for the NHANES normal comparison group; however, the proportion of obese and underweight patients was increased in patients with PAH. Subgroup analysis demonstrated that subgroups with idiopathic PAH and those with PAH associated with drugs and toxins had both higher BMI and percentage of obese patients, whereas 3 other subgroups (those with PAH associated with congenital heart disease, connective tissue disease, and human immunodeficiency virus) had lower mean BMI. Conclusion: Mean BMI of the REVEAL patients was the same as that of the NHANES normal comparison group; however, there were higher percentages of obese and underweight patients in REVEAL. This discrepancy can be explained by the balancing effect of more overweight and underweight patients in different PAH subgroups. The reason for the increased frequency of obesity in idiopathic PAH is unknown, and additional study is needed. Trial Registration: clinicaltrials.gov Identifier: NCT00370214

UR - http://www.scopus.com/inward/record.url?scp=79551664063&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79551664063&partnerID=8YFLogxK

U2 - 10.4065/mcp.2010.0394

DO - 10.4065/mcp.2010.0394

M3 - Article

C2 - 21282484

AN - SCOPUS:79551664063

VL - 86

SP - 105

EP - 112

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 2

ER -

Comparison of body habitus in patients with pulmonary arterial hypertension enrolled in the registry to evaluate early and long-term PAH disease management with normative values from the national health and nutrition examination survey

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this